Clin Appl Thromb Hemost
November 2024
Res Pract Thromb Haemost
February 2023
Background: The optimal dose of tinzaparin for prophylaxis in obese medical patients is not well defined.
Objectives: To evaluate the anti-Xa activity in obese medical patients on tinzaparin prophylaxis adjusted for actual bodyweight.
Methods: Patients with a body mass index of ≥30 kg/m treated with 50 IU/kg tinzaparin once daily were prospectively included.